

Life Sciences & Health - Your Q3/Q4 2026 funding roadmap

Do not miss out on grants and incentives
opportunities

May 2026



The better the question. The better the answer. The better the world works.



Shape the future
with confidence

LSH – latest measures, trends and insights

- **Biotech act**

- The proposed Biotech Act aims to strengthen Europe's biotechnology potential by improving funding options, supporting bio-manufacturing, and easing the path from laboratory research to market. It will simplify regulations, accelerate clinical trial authorisations, establish single regulatory pathways for complex products, and ultimately support the development of innovative therapies and a strong European biotech industry.

- **Safe Hearts Plan**

- Cardiovascular diseases cause 1.7 million deaths annually in the EU, cost €282 billion, and are projected to rise by 90% by 2050. The Safe Hearts Plan introduces the first comprehensive EU strategy with targeted measures to improve prevention, detection and treatment, leveraging personalised tools, digital and AI solutions, reducing health inequalities, and supporting Member States through national plans, dashboards and an AI Incubator.


- **Medical devices**

- The EU medical devices sector employs nearly one million people, is worth €170 billion, and faces high costs, bottlenecks and delays under current rules. The proposed reforms simplify regulations, strengthen the EMA's role, speed up access to safe devices and deliver €3.3 billion in yearly savings.

- **EY Firepower report: life sciences dealmaking – trends in 2026**

- Life sciences dealmaking firepower and M&A growth strategy. Learn how life sciences organizations can accelerate dealmaking strategies to succeed.

Funding roadmap 2026 - Opportunity selection



Relevant grants and incentives in 2026

Programs - Life science and biotech*	Description	Consortium?	Estimated grant range	TRL level	Funding rate	Deadline(s)
<u>WBSO</u>	Dutch fiscal scheme offering tax benefits for companies conducting R&D activities in innovative technologies and processes	No	Project specific	1-8	Max. 50% of eligible costs	Year-round
<u>Innovative Health Initiative - call 13</u>	European public-private partnership that funds collaborative research projects to accelerate the development of innovative healthcare solutions, integrating pharmaceuticals, biotech, medical technology, and digital health	Yes	€5 - 15m	3-8	55%	Expected launch: Summer 2026
<u>EIC Accelerator</u>	European innovation program that provides funding and support for SMEs and startups to scale up and bring high-impact, market-ready innovations to global markets	No	Max. €2.5m + €1-10m equity	6-9	Max. 70%	8 July 2026 2 September 2026 4 November 2026
<u>EIC STEP</u>	New initiative under the European Innovation Council designed to help deep-tech companies scale up internationally by providing large-scale investment (10-30M) and strategic support for growth beyond the EU market	No	€10 - 30m equity	8-9	Investment	9 September 2026 25 November 2026
<u>Eurostars - call 11</u>	European funding program that supports innovative SMEs and their partners in collaborative international R&D projects aimed at developing new products, processes, or services for market introduction	Yes	€500k	4-6	Max. 50%	10 September 2026
<u>Horizon Europe - Health</u>	Funding program under Horizon Europe that supports research and innovation to improve health and well-being, strengthen healthcare systems, and tackle major health challenges across Europe	Yes	€6 - 8m	3-9	Max. 70/100%	15 September 2026
<u>EIC Transition</u>	European innovation program that supports the maturation and commercialization of breakthrough technologies developed in earlier research projects, bridging the gap between lab results and market-ready innovations	Yes/No	Max. €2.5m	4-5	100%	16 September 2026
<u>EIC Pathfinder Challenges</u>	European innovation program that funds early-stage, high-risk research to develop breakthrough technologies with transformative potential	Yes	Max. €4m	1-3	100%	28 October 2026
<u>Innovation Credit</u>	Dutch government loan program that provides risk-bearing financing for innovative development projects with high technical and commercial potential, helping companies bridge the gap between R&D and market introduction	No	€5m-€10m	3-8	Max. 50% of total project costs	31 December 2026

EY Grants & Incentives: value proposition



End-to-end support: from ideation, application, closure, compliance and governance



Digitally-enabled: IncentivesIQ™ and Grants and Incentive Engine™ as workflow and opportunity management tools



Global and local capabilities: our 30 FTE in the Netherlands are connected to our team of 1,000 specialists across 80 countries



Deep expertise, agile teaming: combining technical expertise, fiscal, financial and thematic expertise in one team. Servicing the largest clients globally and in the Netherlands



No-frills delivery: no surprises, clear communication and transparent remuneration models

80+


Countries

170+

Cities

1,000+

Professionals



- Dedicated EY Grants & Incentives resource
- Supported by dedicated EY resource

€25b+

Obtained for our clients to date

EY Grants & Incentives - approach and contact



Opportunity and risk assessment

Our international team of grants & incentives experts can aid you in mapping the right incentives for your operations. The ensuing long- and shortlists focus on timing, feasibility and value and help to devise an appropriate funding strategy. Additionally, compliance experts from our Subsidy Audit Services can identify potential compliance breaches early - contributing towards prevention of potential clawbacks.



End-to-end support

Our experienced team is well-versed all things grants and incentives. Deep technical and subject matter expertise helps to draft compelling, strong funding applications, whereas our knowledge of funding rules and regulations helps to optimize compliance processes.

Our Grants & Incentives services can consist of 1. aligning with your needs, 2. mapping opportunities, 3. deciding and prioritizing, 4. applying and submitting, and 5. ensuring compliance and follow-up.



Governance

As one of the world's largest business advisors we know how organizations work. Our in-house experience and track-record with servicing the largest firms in G&I applications helps us to define efficient, effective processes that ensure 1. timely identification of benefits, 2. efficient application for benefits and 3. effective retention of benefits. We help to define G&I governance processes - be it local, regional or global.



Gerben Wedekind
Partner | Grants & Incentives

gerben.wedekind@nl.ey.com
+31 6 29 07 82 50



Mohammad Tabibi
Manager | Grants & Incentives | Life Sciences & Health

mohammad.tabibi@nl.ey.com
+31 6 29 08 47 81



Florance de Bruin
Consultant | Grants & Incentives | Life Sciences & Health

florance.de.bruin@nl.ey.com
+31 6 21 25 27 47



Julia Regelink
Consultant | Grants & Incentives | Life Sciences & Health

julia.regelink@nl.ey.com
+31 6 21 25 26 90

EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

© 2026 EY Belastingadviseurs B.V.
All Rights Reserved.

ED None
Non-binding

This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax, legal or other professional advice. Please refer to your advisors for specific advice.

ey.com